ENDOCANNABINOIDS RECEPTORS MEDIATED CENTRAL AND PERIPHERAL EFFECTS (REVIEW)
ReviewHumansOther animals
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- What endocannabinoid receptors do in the body: a narrative review of their distribution, signalling pathways, and roles in pain, cognition, feeding, fertility and psychiatric disorders.
What the authors reported
Anandamide, 2-AG and palmitoylethanolamide are described as endocannabinoids, with PEA proposed to bind a 'CB2-like' receptor; the authors summarise CB1 and CB2 distribution and signalling, analgesic actions involving PPAR-alpha, TRPV receptors and COX-2, and possible roles in memory, Alzheimer's disease, schizophrenia and depression. No numbers are given.
Limits of this study
A narrative review in a regional journal, not a trial. Some statements (for example PEA acting through CB2-like receptors) reflect the authors' framing. No DOI. Funding and conflicts not stated in the abstract.
Source
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.